February 2, 2018 / 7:57 AM / 21 days ago

BRIEF-Crossject Announces FDA Attributed To Zeneo Midazolam The Oprhan Drug Status

Feb 2 (Reuters) - Crossject SA:

* ANNOUNCED ON THURSDAY THAT FDA ATTRIBUTED TO ZENEO MIDAZOLAM THE OPRHAN DRUG STATUS

* CROSSJECT CONFIRMS THE OBJECTIVE OF RA SUBMISSION FOR ZENEO MIDAZOLAM IN 2019, IN THE USA AND IN EUROPE

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below